Checkpoint Therapeutics, Inc.

Equities

CKPT

US1628282063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 15/05/2024 am IST			5-day change	1st Jan Change
1.56 ^USD	+1.30%		-7.69%	-31.88%

10/05	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
22/03	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy

December 18, 2023 at 05:39 pm IST

Dec 18 (Reuters) - Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. (Reporting by Mariam Sunny in Bengaluru)

Latest news about Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Checkpoint Therapeutics, Inc. Appoints Amit Sharma to Its Board as an Independent, Non-Executive Director	18/03	CI
Checkpoint Therapeutics Launches $14 Million Registered Direct Offering	29/01	MT
B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	20/12	MT
Checkpoint Therapeutics Shares Halved After FDA Complete Response Letter	18/12	DJ
U.S. Food and Drug Administration Issues Complete Response Letter for Checkpoint Therapeutics, Inc.'s Cosibelimab Solely Due to Inspection Findings At Third-Party Manufacturer	18/12	CI
US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy	18/12	RE
Checkpoint Therapeutics Gets FDA Response Letter on Cosibelimab Application	18/12	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	20/11	DJ
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer	18/23/18	CI
Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P Global BMI Index	18/23/18	CI
B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	22/23/22	MT
North American Morning Briefing : China Trouble Hits Sentiment	18/23/18	DJ
Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	15/23/15	MT
Ladenburg Thalmann Adjusts Checkpoint Therapeutics' Price Target to $47 From $65, Keeps Buy Rating	15/23/15	MT
Cantor Fitzgerald Adjusts Checkpoint Therapeutics' Price Target to $14 From $19, Keeps Overweight Rating	15/23/15	MT
Checkpoint Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
North American Morning Briefing : Stock Futures -2-	11/23/11	DJ
Checkpoint Therapeutics to Raise $10 Million in Offering of Shares, Warrants; Stock Falls	31/23/31	MT
Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from Russell Microcap Growth Index	23/23/23	CI
Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from Russell 3000E Growth Index	23/23/23	CI
Lake Street Adjusts Checkpoint Therapeutics' Price Target to $16 From $22, Keeps Buy Rating	30/23/30	MT
Ladenburg Thalmann Lowers Price Target on Checkpoint Therapeutics to $65 From $69, Maintains Buy Rating	17/23/17	MT

Chart Checkpoint Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.

Sector

Biotechnology & Medical Research

Calendar

20/05/2024 - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Checkpoint Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.56 USD

Average target price

17.25 USD

Spread / Average Target

+1,005.77%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CHECKPOINT THERAPEUTICS, INC.	-31.88%	5.57Cr
MODERNA, INC.	+29.03%	4.92TCr
IQVIA HOLDINGS INC.	-0.10%	4.21TCr
LONZA GROUP AG	+48.04%	4.04TCr
CELLTRION, INC.	-5.26%	2.89TCr
ICON PUBLIC LIMITED COMPANY	+11.48%	2.61TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.74%	1.87TCr
BIO-TECHNE CORPORATION	+9.06%	1.33TCr
MEDPACE HOLDINGS, INC.	+30.01%	1.23TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.51%	1.2TCr

Other Biotechnology & Medical Research